From various new anthracyclines containing fluorine in their sugar moieties, 7-O-(2,6-dideoxy-2-fluoro-a-L-talopyranosyl)adriamycinone-1 4-hemipimerate (FAD 1 04) has been selected for clinical investigation, because of its excellent antitumor activity and solubility. In this paper, the mechanism whereby FAD104exhibits good antitumor activity in vivo was studied through experiments in vitro in comparision with doxorubicin (DOX). FAD104 had weaker activity than DOXin DNAsingle and double strand scission in P388 cells and in binding to calf thymus DNA.FAD104was taken up by P388 cells faster than DOX. The ester linkage in FAD104 was gradually hydrolyzed at neutral pH. FAD104 was metabolized to 7-0-(2,6-dideoxy-2-fluoro-a-L-talopyranosyl)adriamycinone (FT-ADM)when incubated with mouse or humanserum. In mouse serum the esterase activity was about 100 times higher than in humanserum. The product of nonenzymatic and enzymatic esterolysis, FT-ADM,was rapidly taken up by P388 cells and accumulated, reaching at a 9.7-fold higher level than DOX. Thus FAD104was less active than DOXin itself, but it showed much higher activity through conversion into FT-ADM, due to the action of esterase or to spontaneous and gradual hydrolysis at physiological pH. 7-0-(2,6-Dideoxy-2-fluoro-a-L-talopyranosyl)adriamycinol (FT-ADM-OH), another metabolite found in mouse serum had the least biological activity among the fluorine-containing anthracycline glycosides, but its activity was still higher than DOX.
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An anthracycline antibiotic, doxorubicin (DOX) has been clinically important in cancer chemotherapy. It has a wide spectrum of activity against humantumors such as stomach, breast, ovary and bladder cancers, and acute leukemia. Its utility, however, is limited due to irreversible cardiotoxicity and other undesirable side effects. Natural and acquired resistance to muliple drugs including DOXis an important clinical problem. Efforts to make new analogs have been continued by many research groups with the objective of obtaining compounds with superior activity and less cardiotoxicity, and to overcomemulti-drug resistance. Wepreviously discovered aclarubicin (aclacinomycin A) from culture filtrates of Streptomyces galilaeus in 19751}, which had lower general and cardiac toxicities than DOXand was effective against multi-drug resistant cells. It has been used clinically to treat acute myeloid leukemia since 1981. In 1979, pirarubicin (4'-0-tetrahydropyranyladriamycin) was synthesized2) and has been used since 1988 against solid tumors as a drug with less cardiotoxicity and side effects such as nausea, vomitting and hair loss than DOX.In previous papers3~7), we reported syntheses of new fluorine-containing anthracycline glycosides. The electrophilic functional atom, fluorine, was introduced at the C-2 position of the sugar.
Amongst these analogs, 7-0-(2,6-dideoxy-2-fluoro-a-L-talopyranosyl)adriamycinone (FT-ADM) and its 14-O-acyl derivatives had superior antitumor activity and weaker toxicity than DOX.Out of their group 7-O-(2,6-dideoxy-2-fluoro-a-L-talopyranosyl)adriamycinone-1 4-hemipimerate (FAD 1 04) was selected for clinical investigations because of its excellent antitumor activity and solubility: It has good therapeutic activity against leukemia L1210 over a wide dose range, curing many mice, while it showed a good solubility at neutral pH necessary for intravenous administration. In this paper, we report its cytotoxic effect, antitumor activity, DNAstrand scission, inhibition of nucleic acid synthesis, DNAbinding, uptake and retention by cultured cells. FT-ADM and 7-O-(2,6-dideoxy-2-fluoro-a-L-talopyranosyl)adriamycinol (FT-ADM-OH) are both observed in the plasma of mice, rats (Meiji Seika Kaisha; personal communication) and rabbits (H. Fujita; personal communication) after administration of FAD104. FAD104is predicted to be metabolized to FT-ADM by cellular and/or serum carboxylesterase like 7V-(trifluoroacetyl)adriamycin 14-0-hemiester derivatives8* and subsequently to FT-ADM-OH.We, therefore studied the hydrolysis of FAD104by serum esterase and by spontaneous hydrolysis without enzyme, and the biological activities of the products, FT-ADMand FT-ADM-OH,together. [3H]thymidine were irradiated with 150R ofX-ray on ice, and used as an internal standard. Cells (5 x 105) treated with drug were mixed with the same amount of the X-ray irradiated internal standard cells, and deposited onto a polycarbonate membrane filter (25mm diameter, 2jum pore size, Nucleo-pore, Pleasanton, CA, U.S.A.) in a Swinnex 25 filter holder (Millipore Co., Bed ford, MA, U.S.A.), washed with cold phosphate-buffered saline (pH 7.2) without Ca++ and Mg++(PBS) and lysed for lhour in 5ml of a solution containing 0.1m glycine, 0.025m Na2EDTAand 2% SDS, and 0.5mg/ml proteinase K, pH 9.6. The elution offragmented DNAwas performed in the dark with 40ml ofa solution containing 0.02m EDTA, 0.1% SDS plus tetrapropylammonium hydroxide, pH 12.2, at a flow rate of 0.035~0.045 ml/minute using a multichannel peristaltic pump (model IPS-16, Ismatic Co., Swiss). Fractions were collected at 1-hour intervals and each fraction was neutralized with 0.3~0.75% acetic acid, mixed with 3.5 ml of Atomlite scintillation cocktail (New England Nuclear, Boston, U.S.A.), and processed for radioactive counting. Radioactivity remaining on the filter after elution was determined upon treatment with 0.4ml of 1N HC1 for 1 hour at 65°C and subsequent addition of 1ml of In NaOHand Atomlite. Resulting 14C and 3H dpm of the eluted fractions were expressed as fraction of the total dpm resulting from the sum of dpmin the eluted fractions and the extract from the filter for each treatment. The fraction of 14C DNAretained on the filter was plotted vs. 3H DNAinternal standard retained on the filter.
Materials and Methods

Materials
In determination of DNAdouble strand breaks, 2.5 x 105 cells labeled with [14C]thymidine and treated with drug were processed in the same wayas for single-strand breaks except that the pH of eluting solution was 9.6. Internal standard cells were not used, because this method was known to be influenced by total cell number. The 14C retained on the filter was plotted vs. the time of elution.
Inhibition of Nucleic Acid Synthesis
Nucleic acid synthesis was determined using a modified method of Matsuzawa et al. n) . L5178Y Cells in exponential phase of growth were suspended in RPMI1640medium-10mMHEPES,pH 7.2. After preincubation of cells (5.5 x 105/ml, 85 /A) with various concentrations of drugs (5^1) at 37°C for 30 minutes or without preincubation, [raer/*y/-3H]thymidine (0. 1 /xCi, 10 fil) or [5-3H] uridine (3 /iCi, 10 /il) was added and the mixture was incubated for 1 hour. The reaction was stopped by the addition of 1 ml of cold 5% TCA. After standing in an ice bath for 15minutes, the acid-insoluble fraction was collected using an Eppendorf microcentrifuge. The precipitate was washed with 1 ml of cold TCAtwice, and solubilized by treatment with 0.3ml of 0.5n KOHat 60°C for 30minutes. Radioactivity was measured using 1.5ml of PCS scintillation cocktail (Amersham Co., U.S.A.).
Drug Uptake and Efflux Drug uptake and efflux were determined by fluorometry as previously described12). P388 Cells were harvested from ascitic fluid, washed by centrifugation repeatedly, and suspended in RPMI1640 medium-10mMHEPES, pH 7.2. For uptake experiments cell suspensions (2x l06/ml, 0.4ml in an Eppendorf tube) were incubated with 0.1 ml of drug solution (21.25^m or 2.125^m) in the same medium at 37°C. Uptake was terminated by centrifugation at 12,000xg for 30 seconds in an Eppendorf microcentrifuge. After washing with 1 ml of cold PBS the cells were disrupted by ultrasonication in 1 ml of PBS. Drugs were extracted from 0.8ml portions of the sonicated cell suspensions by the addition of 2ml of 40% TCAand 0.3ml of 3.3% bovine serum albumin and overnight incubation. The incubated mixtures were centrifuged and fluorescence intensity at 598 nm was determined using a Hitachi MPF-4 spectrofluorometer with an excitation wavelength of 500 nm. Whendrug uptake at low drug concentration was examined, bovine serum albumin was not added to avoid nonspecific adsorption of the anthracyclines to the protein.
For efflux experiments P388 cells (2.6 x 106/ml, 10ml) were preloaded by incubation for 15 minutes at 37°C with PBS -10mM NaN3 containing DOX (70/zg/ml), FAD104 (75 /ig/ml), FT-ADM (8 /ig/ml) or FT-ADM-OH (15/ig/ml). Cells were centrifuged, suspended in 12ml of cold fresh RPMI1640 medium-10mMHEPES, pH 7.0, and incubated at 37°C. Time-dependent increases of concentration of effluxed drug from the cells into the medium was determined using fluorescence after TCAextraction. Hydrolysis of Ester Bond of FAD104 Determination of FAD104and FT-ADM after enzymatic or nonenzymatic treatment was done using HPLC. The incubation mixture (0.5 ml) contained FAD104and mouse, horse, or human serum, or purified hog liver esterase in various buffer solutions. After incubation the pH was adjusted to less than 2 with 1 n HC1. Drugs were extracted by shaking with 1.5 ml ethyl acetate. The ethyl acetate layer was separated and dried in an evaporator then dissolved in 0.5 ml Britton-Robinson buffer, pH 3.0 and methyl alcohol mixture (1 :2) containing 25/zg/ml DOXas an internal standard for HPLC. The HPLCsystem was composed of SP8700 solvent delivery system, S8750 organizer as the injector (Spectra-Physics, Co., U.S.A.), Y-2100 incubator and Y-1000 UV detector (Senshu Scientific Co., Japan) with Chromatocorder 1 1 (System Instruments, Co., Japan) as the recorder. Samples were eluted with a mixture of 0.05 msodium acetate buffer, pH 5.6 and acetonitrile (65 : 35) at 30°C at a flow rate of 1.0ml/minute using a column of Inertsil ODS5 Aim, 4.6 x 250 mm(Gasukuro Kogyo Inc., Japan). Retention times of DOX, FAD104, and FT-ADM were approximately 6.4, 17.9 and 1 1.7 minutes, respectively. In these experiments FT-ADM-OH was not detected.
Results
Antitumor Activity
The antitumor activity of FAD104and its metabolites, FT-ADMand FT-ADM-OH against L1210 is shown in Fig. 2 . FT-ADMand FT-ADM-OH are sparingly soluble in water or buffer, hence they were administered as solutions in phosphate buffer pH 7.4 containing 5% DMSOas shown in the legend of Fig. 2 . Many mice administered with FAD104 and FT-ADMsurvived for 60 days. FAD104 and FT-ADM had much superior antitumor activity to DOX. FT-ADM-OH had inferior activity to FAD104 or FT-ADM, but it did not kill as many mice in the 60-day period as DOX.In their model FAD104showed the best antitumor activity and the least toxicity among the drugs tested. Table 1 . FAD104 and FT-ADMshowed stronger cytotoxicities against L1210, L5178Y and P388 cells than DOX. FT-ADM-OHshowed about the same cytotoxicity as DOX.All the compounds showed less activity on P388/ADRcells than on other cells. However, FAD104 and FT-ADMinhibited the growth ofP388/ADRcells at about a 10 times lower concentration than DOX. DNAStrand Scission Anthracycline-induced strand scission was studied using the filter elution method. P388 Cells were incubated with 2.8 jum of drug for 1 hour, washed twice with cold medium and analyzed for DNAsingle-and double-strand scissions at pH 12.2 and 9.6, respectively.
As shown in Fig. 3 , DNAsingle-strand (A) and double-strand (B) breaks were observed for the three fluorine-containing compounds and DOX.FT-ADM gave the greatest damage to DNA.The effect of FAD104was smaller than that of DOXon single-strand breaks and equal to DOXon double-strand breaks, although its cytotoxic effect was stronger than DOX. FT-ADM-OH was similar to DOXin both single and double strand DNAscission. DNAsingle-and double-strand breaks were measured by filter elution method at pH 12.2 (A) and pH 9.6 (B), respectively, in the presence of protease K. See "Materials and Methods" for details. Table 2 all the fluorine-containing anthracyclines inhibited DNAand RNAsynthesis in intact L5178Y cells. No selectivity in inhibition of RNAsynthesis over DNAsynthesis was observed with all the agents including DOX. Introduction of the fluorine group did not give selective inhibition of DNA or RNAsynthesis. The order of potencies of nucleic acid synthesis inhibition was FT-ADM,FAD104, FT-ADM-OHand DOX.
DNA-Binding
The calf thymus DNA-binding characteristics of the agents were studied using the fluorescence titration technique. Table 3 lists apparent association constant (Kapp) and apparent number of binding sites (napp). These values were obtained from a Scatchard analysis of the interaction of these agents with calf thymus DNA. DOXhad the strongest affinity for DNA.The Kapp of FAD104and FT-ADM-OHwere markedly lower than that of DOX.Some differences were seen in the values of napp among these drugs, but the accuracy of this analysis in determining the size of the binding site has not been established.
Drug Uptake and Efflux Uptake of FAD104, FT-ADMand FT-ADM-OHby P388 cells in RPMI1640 medium containing 10him HEPES, pH 7.2, were compared with the uptake of DOX.As shown in Fig. 4(A) , where the initial drug concentration was 17 /^m, FAD104was taken up by P388 cells slightly faster than DOX. FT-ADMwas much more rapidly incorporated than either DOXor FAD104. After 20minutes FAD104 and FT-ADMwere accumulated 2.25 and 9.73-fold, respectively, more than DOX.FT-ADM-OH was taken up into P388 cells much more slowly than FT-ADMas shown in Fig. 4(B) , where the initial concentration of all the drugs was 1.7/iM, or one tenth of that used in the experiment shown in Fig.   3(A) . This lowering of drug concentration was necessitated because of the low solubility of
Efflux kinetics of these agents from P388 cells was shown in Fig. 5 . Initial rates of efflux of FT-ADM. FT-ADM-OH and DOX were different from each other, but the proportion of drugs retained at equilibria were similar. However, FAD104was more rapidly released from the cells and its retention was lower at equilibrium than DOX.
Hydrolysis of Ester Bond of FAD104 As described above, FAD104had the strongest antitumor activity, but it had the least activity in the DNA-binding assay. DNAstrand scission activity of FAD104was also lower than DOXin spite of its faster uptake. The intracellular accumulation of FAD104does not seem sufficient to account for its strong antitumor activity. On the other hand, FT-ADMshowed the strongest cytotoxicity and the fastest uptake Conversion by esterase was calculated by subtracting FT-ADM (%) without serum from that with serum.
among the fluorine-containing anthracyclines. HPLCanalysis of serum of animals after administration of FAD104 showed the formation of FT-ADM and FT-ADM-OH6'7).For this reason spontaneous and enzymatic hydrolysis of the ester bond of FAD104 was determined. As shown in Fig. 6 , FAD104 was gradually hydrolyzed at a pH range between 6.5 and 8.0. At pH 9.0 it was rapidly hydrolyzed to FT-ADM as was expected for an ester. A nonspecific esterase exists in plasma and cells. The conversion of FAD104to FT-ADMby esterase in serum was tested at pH 7.4 and 5.7 with a long incubation time in order to distinguish this enzyme action from alkaline hydrolysis. As shown in Table  4 , FAD104was rapidly hydrolyzed by mouse serum but only slowly hydrolyzed by human serum. Horse 
FAD104
(100//g/ml) was dissolved in various buffers. Acetate buffer, sodium phosphate buffer, and Tris-HCl buffer were used at 0.02m at pH 5, pH 6-8, or pH 9, respectively. After incubation at 37°C for 1.5 hours reaction was stopped by addition of 1 n HC1 to adjust to pH 2 and analyzed as described in "Materials and Methods".
serum had an intermediate activity.
The result obtained at pH 5.7 showed that esterase activity hydrolyzing the carboxylic acid ester ofFAD104was about 100 times more active in mouse serum than in human serum.
Discussion
In this report we describe the antitumor activity and biochemical properties of the newly developed fluorine-containing anthracycline glycoside, FAD104, and its metabolites, FT-ADMand FT-ADM-OH. FAD104had the highest antitumor activity against mouse L1210 leukemia5'6*. FT-ADMhad nearly equal activity to FAD104but had higher toxicity as shown in Fig..2. FT-ADM-OH showed weaker antitumor activity than FAD104or FT-ADM.Some biochemical properties of these compounds were tested to elucidate the mechanism of antitumor activity. Cytotoxic activity was the strongest for FT-ADM. FAD104 showed a much stronger cytotoxic activity than DOX,but weaker than FT-ADM.FT-ADM-OH had a similar cytotoxic activity to DOX.It is of interest to note that FAD104was more active against multi-drug resistant P388 cells (P388/ADR) than DOXand the IC50 of FAD104 was less than one tenth of DOX as shown in Table 1 . It appears reasonable to expect that FAD104will be active against clinical tumors which are not so severely resistant to DOX,because FAD104can be administered in 10 times higher amount of DOXbecause of its less acute toxicity. Tsuruo et al.13 ) reported that FAD104did not show antitumor activity against P388/ADRleukemia, but was effective against P388/VCRwhich was also multi-drug resistant, but its resistance was lower than shown by P388/ADR.
It appears that breakdown of the ester bond of FAD104due to a metabolic activity or to the instability of the bond has an important role in exerting the in vivo antitumor activity of the drug. FAD104itself has biological activity as shown in DNA-binding ability (Table 3 ), but FT-ADMhas the stronger activity in DNAstrand scission (Fig. 3) , inhibition of nucleic acid synthesis ( Table 2 ) and intercalation to double stranded DNA (Table 3 ) than FAD104. The former two activities might be caused mostly by higher intracellular accumulation of FT-ADM but the last activity uses a cell free system that does not involve drug incorporation and metabolism. The conversion of FAD104 to FT-ADM progressed both spontaneously and enzymatically as shown in Fig. 6 and Table 4 . Different species of animals had different enzyme activities in hydrolyzing the ester bond of FAD104. Mouse serum had approximately 100 times higher activity than human serum, and horse serum had an intermediate activity. Such diversity in enzyme activities in sera and organs is thought to influence drug distributions and effects of the drug in different organs: As the uptake ofFAD104into cells occurs at a slower rate than that ofFT-ADM,and the FAD104 taken up is released by the cells rapidly, it appears that FAD104may remain in the bloodstream for a long time, and FT-ADMis incorporated rapidly into target tissues as it is gradually formed in the bloodstream, hence a strong antitumor activity is maintained. A clinical investigation of FAD104 is now in progress as ME2303 in Japan. Further studies such as studies on in vitro biochemical activity, pharmacokinetics, in vivo metabolism, etc. are needed to elucidate the biological mechanisms responsible for the strong antitumor activity of FAD104. These studies are currently in progress in our laboratory.
